Aligos Therapeutics ALGS
NASDAQ ALGS
$4.84 -0.12 (-2.42%)
As of: Oct 22, 2026 · 3:58 PM EDT

Aligos Therapeutics (ALGS) Non-Current Deffered Revenue (2020 - 2022)

Updated

Aligos Therapeutics' Non-Current Deffered Revenue was $1.56 million in Q3 2022, up 13.5% from $1.37 million a year earlier but down 52.2% from the prior quarter.

Analysis

Aligos Therapeutics (ALGS) Non-Current Deffered Revenue (2020 - 2022) Analysis & Trends

At the end of FY2020, Non-Current Deffered Revenue at Aligos Therapeutics came in at $4.11 million.

  • Quarterly Non-Current Deffered Revenue has moved between $1.37 million (Q3 2021) and $5.01 million (Q1 2022) over five years.
  • Compared with a year earlier, Non-Current Deffered Revenue has increased for three straight quarters.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Deffered Revenue (Qtr)
1 Eli Lilly 1,165.22 Bn 1,133.81 Bn 19.71 Bn -
2 Johnson & Johnson 646.28 Bn 566.14 Bn 17.30 Bn -
3 AbbVie 503.17 Bn 476.28 Bn 12.70 Bn -
4 Merck 365.23 Bn 319.60 Bn 12.21 Bn -
5 Novartis Ag 302.66 Bn 266.65 Bn 11.24 Bn -
6 Astrazeneca 267.39 Bn 241.08 Bn 12.86 Bn -
7 Amgen 241.61 Bn 197.01 Bn 7.24 Bn -
8 Gilead Sciences 194.67 Bn 168.86 Bn 6.22 Bn -
9 Pfizer 172.91 Bn 119.55 Bn 10.94 Bn -
10 Aligos Therapeutics 49.86 Mn -278.55 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2022 1.56 Mn
Jun 30, 2022 3.25 Mn
Mar 31, 2022 5.01 Mn
Sep 30, 2021 1.37 Mn
Jun 30, 2021 2.73 Mn
Mar 31, 2021 3.51 Mn
Dec 31, 2020 4.11 Mn
API Access

Aligos Therapeutics Non-Current Deffered Revenue API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=non-current-deffered-revenue&ticker=ALGS&period=max&api_key=YOUR_API_KEY